Moderate-Hypofractionated Radical Radiotherapy for Early-Stage Prostate Cancer: A Propensity Score Matching Analysis Comparing Dose Fractionation Patterns.

IF 2.5 4区 医学 Q3 ONCOLOGY
Cancer Control Pub Date : 2025-01-01 Epub Date: 2025-04-12 DOI:10.1177/10732748251330058
Yinjie Tao, Weishi Cheng, Hongnan Zhen, Jing Shen, Hui Guan, Xiaorong Hou, Ke Hu, Fuquan Zhang, Zhikai Liu
{"title":"Moderate-Hypofractionated Radical Radiotherapy for Early-Stage Prostate Cancer: A Propensity Score Matching Analysis Comparing Dose Fractionation Patterns.","authors":"Yinjie Tao, Weishi Cheng, Hongnan Zhen, Jing Shen, Hui Guan, Xiaorong Hou, Ke Hu, Fuquan Zhang, Zhikai Liu","doi":"10.1177/10732748251330058","DOIUrl":null,"url":null,"abstract":"<p><p>IntroductionThis study evaluates the clinical outcomes, survival benefits, and toxicities of two moderate-hypofractionated radiotherapy (MHRT) patterns, 60 Gy in 20 fractions (60 Gy/20f) and 70 Gy in 28 fractions (70 Gy/28f), in early-stage prostate cancer patients.MethodsThis retrospective study analyzed data from 187 patients diagnosed between 2014 and 2023, using propensity score matching to ensure efficacy assessment accuracy. The primary endpoints reported were overall survival (OS) and disease-free survival (DFS), calculated using Kaplan-Meier analysis. Toxicity and side effects were evaluated using Criteria for Adverse Events v5.0, focusing on the urinary and gastrointestinal (GI) systems.ResultsAfter matching, each of the 60 Gy and 70 Gy groups included 73 patients. The median follow-up duration for all patients was 36.0 months. The OS rates for the 60 Gy and 70 Gy groups were 86.3% and 89.0%, respectively, with 3-year OS rates of 92.4% and 89.0% (<i>P</i> = 0.375). The 3-year DFS rates were 91.0% in the 60 Gy group and 81.0% in the 70 Gy group (<i>P</i> = 0.096), indicating no significant differences between the groups. The incidence of acute Grade 2 or higher urinary toxicities was comparable between the two groups (60 Gy group vs 70 Gy group: 9.6% vs 9.6%, <i>P</i> = 1.0), while the 70 Gy group demonstrated an advantage for late Grade 2 or higher toxicities (60 Gy group vs 70 Gy group: 12.3% vs 2.8%, <i>P</i> = .028). For the GI system, the incidence of acute toxicities was higher in the 60 Gy group, albeit not statistically significant (60 Gy group vs 70 Gy group: 11.0% vs 6.8%, <i>P</i> = .383), while late toxicities were equivalent between the groups (60 Gy group vs 70 Gy group: 1.4% vs 1.4%, <i>P</i> = 1.0).ConclusionBoth MHRT fractionation patterns demonstrate comparable survival outcomes and toxicities in early-stage prostate cancer, suggesting MHRT's viability as a primary treatment. The 60 Gy/20f pattern marginally favored survival, albeit not with statistical significance.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251330058"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033645/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Control","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10732748251330058","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

IntroductionThis study evaluates the clinical outcomes, survival benefits, and toxicities of two moderate-hypofractionated radiotherapy (MHRT) patterns, 60 Gy in 20 fractions (60 Gy/20f) and 70 Gy in 28 fractions (70 Gy/28f), in early-stage prostate cancer patients.MethodsThis retrospective study analyzed data from 187 patients diagnosed between 2014 and 2023, using propensity score matching to ensure efficacy assessment accuracy. The primary endpoints reported were overall survival (OS) and disease-free survival (DFS), calculated using Kaplan-Meier analysis. Toxicity and side effects were evaluated using Criteria for Adverse Events v5.0, focusing on the urinary and gastrointestinal (GI) systems.ResultsAfter matching, each of the 60 Gy and 70 Gy groups included 73 patients. The median follow-up duration for all patients was 36.0 months. The OS rates for the 60 Gy and 70 Gy groups were 86.3% and 89.0%, respectively, with 3-year OS rates of 92.4% and 89.0% (P = 0.375). The 3-year DFS rates were 91.0% in the 60 Gy group and 81.0% in the 70 Gy group (P = 0.096), indicating no significant differences between the groups. The incidence of acute Grade 2 or higher urinary toxicities was comparable between the two groups (60 Gy group vs 70 Gy group: 9.6% vs 9.6%, P = 1.0), while the 70 Gy group demonstrated an advantage for late Grade 2 or higher toxicities (60 Gy group vs 70 Gy group: 12.3% vs 2.8%, P = .028). For the GI system, the incidence of acute toxicities was higher in the 60 Gy group, albeit not statistically significant (60 Gy group vs 70 Gy group: 11.0% vs 6.8%, P = .383), while late toxicities were equivalent between the groups (60 Gy group vs 70 Gy group: 1.4% vs 1.4%, P = 1.0).ConclusionBoth MHRT fractionation patterns demonstrate comparable survival outcomes and toxicities in early-stage prostate cancer, suggesting MHRT's viability as a primary treatment. The 60 Gy/20f pattern marginally favored survival, albeit not with statistical significance.

中度低分割放射治疗早期前列腺癌:比较剂量分割模式的倾向评分匹配分析。
本研究评估了两种中度低分割放疗(MHRT)模式的临床结果、生存益处和毒性,60 Gy分20次(60 Gy/20f)和70 Gy分28次(70 Gy/28f),用于早期前列腺癌患者。方法回顾性分析2014 - 2023年诊断的187例患者资料,采用倾向评分匹配法确保疗效评估的准确性。报告的主要终点是使用Kaplan-Meier分析计算的总生存期(OS)和无病生存期(DFS)。使用不良事件标准v5.0评估毒性和副作用,重点是泌尿和胃肠道(GI)系统。结果经配对后,60 Gy组和70 Gy组各纳入73例患者。所有患者的中位随访时间为36.0个月。60 Gy组和70 Gy组的总生存率分别为86.3%和89.0%,3年总生存率分别为92.4%和89.0% (P = 0.375)。60 Gy组3年DFS为91.0%,70 Gy组为81.0% (P = 0.096),两组间差异无统计学意义。两组间急性2级或更高级别泌尿毒性的发生率相当(60 Gy组vs 70 Gy组:9.6% vs 9.6%, P = 1.0),而70 Gy组在晚期2级或更高级别毒性方面表现出优势(60 Gy组vs 70 Gy组:12.3% vs 2.8%, P = 0.028)。对于胃肠道系统,60 Gy组的急性毒性发生率更高,尽管没有统计学意义(60 Gy组对70 Gy组:11.0%对6.8%,P = 0.383),而两组之间的晚期毒性相当(60 Gy组对70 Gy组:1.4%对1.4%,P = 1.0)。结论两种MHRT分治方式在早期前列腺癌的生存结果和毒性方面具有可比性,提示MHRT作为主要治疗方法的可行性。60戈瑞/20戈瑞的模式略微有利于生存,尽管没有统计学意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Control
Cancer Control ONCOLOGY-
CiteScore
3.80
自引率
0.00%
发文量
148
审稿时长
>12 weeks
期刊介绍: Cancer Control is a JCR-ranked, peer-reviewed open access journal whose mission is to advance the prevention, detection, diagnosis, treatment, and palliative care of cancer by enabling researchers, doctors, policymakers, and other healthcare professionals to freely share research along the cancer control continuum. Our vision is a world where gold-standard cancer care is the norm, not the exception.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信